Get started
Author

Nina E. Weisser

Observed names: Nina Weiser, Nina Weisser
Institution: Zymeworks (Canada)
ORCID: 0000-0002-9903-2429
Observed ORCID: 0000-0002-9903-2429
OpenAlex ID: A5017732395
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics
2009 · Nina E. Weisser, J. Christopher Hall · Biotechnology Advances · 274
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
2023 · Nina E. Weisser, Mario Sanches, et al. · Nature Communications · 209
PDF
Molecular Recognition of Candida albicans (1→2)-β-Mannan Oligosaccharides by a Protective Monoclonal Antibody Reveals the Immunodominance of Internal Saccharide Residues
2012 · Margaret A. Johnson, Jonathan Cartmell, et al. · Journal of Biological Chemistry · 42
PDF
Abstract 31: Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers
2017 · Nina Weisser, Grant Wickman, et al. · Cancer Research · 38
Abstract 1005: The bispecific antibody zanidatamab's (ZW25's) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers
2021 · Nina E. Weisser, Grant Wickman, et al. · Cancer Research · 20
A rAb screening method for improving the probability of identifying peptide mimotopes of carbohydrate antigens
2007 · Nina E. Weisser, Kurt C. Almquist, et al. · Vaccine · 10
Abstract 1032: Super-resolution imaging studies of zanidatamab: Providing insights into its bispecific mode of action
2021 · Surjit Dixit, Libin Abraham, et al. · Cancer Research · 5
AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design
2020 · Mario Sanches, Igor D’Angelo, et al. · mAbs · 5
Abstract 6719: TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve responses in the treatment of solid tumors
2024 · Lisa Newhook, Purva Bhojane, et al. · Cancer Research · 3
Abstract 5121: TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors
2023 · Lisa Newhook, Purva P. Bhojane, et al. · Cancer Research · 3
Abstract 6716: DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 costimulation for the treatment of DLL3-expressing cancers
2024 · Peter Repenning, Desmond Lau, et al. · Cancer Research · 2
Abstract 2926: PROTECTTM, a novel trispecific antibody masking platform with integrated immune modulation displays unique activity and differentiated modes of action
2023 · Anna von Rossum, Genevieve Desjardins, et al. · Cancer Research · 2
Complexes with anti-epitope tag IgGs improve the therapeutic potential of epitope-tagged antibody fragments
2010 · Xuemei Xie, Nina E. Weisser, et al. · Molecular Immunology · 2
Abstract 3503: ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers
2025 · Nicole J. Afacan, Patricia Zwierzchowski, et al. · Cancer Research · 1
Abstract 7318: ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer
2025 · Desmond Lau, Peter Repenning, et al. · Cancer Research · 1
Abstract 2982: TriTCE CPI, next generation trispecific T cell engagers with integrated checkpoint inhibition (CPI) for the treatment of solid tumors
2023 · Maya C. Poffenberger, Meghan M. Verstraete, et al. · Cancer Research · 1
Abstract 4542: Zanidatamab modulates multiple pathways involved in tumor growth and survival and is efficacious post T-DXd
2026 · Ankur Karmokar, Emanuele Loro, et al. · Cancer Research
1196 TriTCE Co-stim: a differentiated T cell engager platform with conditional cis CD28 co-stimulation is transferable to diverse targeting strategies
2025 · Chayne L Piscitelli, Diego Perez Escanda, et al. · Journal for ImmunoTherapy of Cancer
PDF
853 Design of a next generation tumor targeted masked IL-12Fc for enhanced tolerability and localized anti-tumor activity
2025 · Nichole Escalante, Sifa Arrafi, et al. · Journal for ImmunoTherapy of Cancer
PDF
1372 TriTCE Co-Stim: a novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors
2023 · Lisa Newhook, Purva Bhojane, et al. · Journal for ImmunoTherapy of Cancer
PDF
1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
2023 · Meghan M Verstraete, Maya Poffenberger, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 2942: ZW171, a T cell-engaging, bispecific antibody for the treatment of mesothelin-expressing solid tumors
2023 · Nicole J. Afacan, Chayne Piscitelli, et al. · Cancer Research
ZW38, a bispecific CD3 x CD19 azymetric antibody to deplete human leukemic B cells by the “controlled” activation of T cells.
2015 · Gordon Ng, Nina Weisser, et al. · Journal of Clinical Oncology
Works count: 23
Citation count: 618
H-index: 6
I10-index: 6
Year
Topic
Type